SecBot SecBot

ROIV

Roivant Sciences Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. D0· CIK 0001635088 Biotech & Drug Discovery
$35.94 −0.55 (−1.51%)
Oct 26 4:00 PM ET · prev $36.49
Market cap
$27.1B
Large cap
Consensus
Buy
90% Buy or better · 20 analysts
Median target
$47.00
+31% · range $41.00–62.00
1 year
+91.1%
from $18.81 · Oct 27
30 days
−2.8%
from $36.98
52-week range
$18.41–41.81
−14% from high · low Oct 28
Avg volume 20D
6.37M
Oct 21 spike 16.84M
Short interest
39.30M
≈5.4% of shares · +8.6%
Days to cover
4.4
at average volume
Insider net
−$36.9M
0 buyers · 4 sellers · since Aug 18
New fund stakes
2
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BULLISH 11 reports · 90 days
Balance 1 bearish · 4 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 9/11
Strongest BULLISH Roivant and its subsidiary Priovant announced positive Phase 3 results for brepocitinib in non-infectious…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $36.9M.

  • InstitutionsBULLISH

    Q2 2026: 48 added (2 new), 31 trimmed or exited. Largest new: Squarepoint Ops $16.8M, Parnassus Investments $13.0M.

  • AnalystsBULLISH

    18 of 20 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.397 → −$0.450 over 90 days. 0 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest +8.6% to 39.30M shares. 4.4 days to cover, ≈5.4% of shares.

  • TrendDOWNTREND

    2% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$29.8M
in new stakes
FundMoveSharesValue
GOLDMAN SACHS GROUP INCADD18,556,458$656.7M
FARALLON CAPITAL MANAGEMENT, L.L.C.ADD14,309,000$506.4M
CITADEL ADVISORS LLCDOUBLED5,576,261$197.3M
DIMENSIONAL FUND ADVISORS LPTRIM5,230,417$185.1M
PRICE T ROWE ASSOCIATES INC /MD/TRIM4,816,741$170.5M
JENNISON ASSOCIATES LLCADD4,481,964$158.6M
Point72 Asset Management, L.P.DOUBLED4,473,478$158.3M
BANK OF AMERICA CORP /DE/ADD4,341,381$153.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 90% rate it Buy or better
Strong Buy9Buy9Hold2Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +31%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026Wolfe Research
DOWNGRADE
DOWNGRADEPeer Perform
Sep 17, 2026Stifel
INITIATE
INITIATEBuy
Sep 9, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Sep 9, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 8, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 8, 2026Jefferies
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$36.9M
sold · 4 insiders
DateInsiderTypeValue
Oct 20, 2026
Venker Eric
President & Immunovant CEO
SELL$6.5M
Oct 20, 2026
Venker Eric
President & Immunovant CEO
SELL$501.0K
Oct 16, 2026
Gline Matthew
CEO
TAX W/H$1.2M
Oct 16, 2026
Sukhatme Mayukh
President & CIO
TAX W/H$669.8K
Oct 1, 2026
Epperly Melissa B,
Director
EXERCISE$79.2K
Oct 1, 2026
Epperly Melissa B,
Director
SELL$607.9K
Oct 1, 2026
Epperly Melissa B,
Director
SELL$32.9K
Sep 30, 2026
Venker Eric
President & Immunovant CEO
EXERCISE$770.0K

Earnings setup

Estimates
−$0.45
EPS estimate, this quarter
−14%
estimate change, 90 days
0↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.45-$0.59–-$0.35+0.0%$3.7M
Next Q-$0.41-$0.53–-$0.35+0.0%$12.3M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
39,296,630
shares short
+8.6%
vs prior settlement
4.4
days to cover
≈5.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Roivant and its subsidiary Priovant announced positive Phase 3 results for brepocitinib in non-infectious uveitis…
8-K — Impact 7/10
Oct 20, 2026 Insider
Venker Eric sold 185,856 shares
President & Immunovant CEO @ $35.09 ($6.5M)
Oct 20, 2026 Insider
Venker Eric sold 14,144 shares
President & Immunovant CEO @ $35.42 ($501.0K)
Oct 16, 2026 Insider
Gline Matthew surrendered for taxes 34,638 shares
CEO @ $33.53 ($1.2M)
Oct 5, 2026 SEC
Roivant Sciences insiders executed $7.93M in net selling, dominated by President & Immunovant CEO Eric Venker's…
CLUSTER — Impact 4/10
Sep 30, 2026 FDA PDUFA
PDUFA: ROIV — brepocitinib in dermatomyositis — 2026-09-30
FDA target action date 2026-09-30 for ROIV (Roivant Sciences Ltd.). Drug: brepocitinib. Indication:
Sep 17, 2026 SEC
Two Roivant Sciences directors sold a combined ~$359K in open-market transactions on September 15, 2026. The sales are…
CLUSTER — Impact 2/10
Aug 27, 2026 Press
FDA approved LISRAYA (brepocitinib) for adult dermatomyositis, the first targeted therapy for this indication…
Impact 8/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
FDA decision date
PDUFA: ROIV — brepocitinib in dermatomyositis — 2026-09-30
FDA target action date 2026-09-30 for ROIV (Roivant Sciences Ltd.). Drug: brepocitinib. Indication: dermatomyositis. FDA assigned PDUFA target…
Sep 8, 2026
FDA
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its…
Sep 6, 2026
FDA
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results…
Aug 27, 2026
FDA
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug…
Aug 27, 2026
FDA
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…

SecBot reports

17 filings · 6 press releases · 1 bullish · 2 bearish · 3 mixed · 11 neutral
All ROIV filing & press-release reports (23)